+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of antihistamine unresponsive chronic urticaria



Treatment of antihistamine unresponsive chronic urticaria



Annales de Dermatologie et de Venereologie 130(Hors Serie 1): 1S78-1S85, Mai



Urticaria is a syndrome. Several signalisation factors (cytokines and chemokines) are implicated in activation of mast cells receptors. Immunologic or non immunologic mechanisms elicit mediator releases and inflammatory activities inducing urticaria lesions. In chronic urticaria the removal of an hypothetical cause is not possible, and the therapeutic management is first oriented towards palliation of symptoms. H1 antagonists are the treatment of choice. Higher dosage than those recommended may be necessary. But severely affected patients are not enough improved. Triggering factors should be avoided. Addition of other mediator antagonists such as leukotriene receptor antagonists have improved some patients and need further evaluation. Several alternative pathogenic therapies have been proposed with conflicting results. Tolerance induction may be tried in a few cases of severe physical urticaria. Oral steroids are reserved if possible for systemic urticaria and in short course for severe exacerbation. Immunosuppressive agents are only appropriate for patients with refractory urticaria to classical treatment. Oral cyclosporine has been used with encouraging results. Its has a suspensive effect but relapses can be treated by H1 antagonists. Whichever the drug or association of drug individual variations in the course of the disease need periodic reevaluation. A spontaneous unexplained remission is not an exception. In this heterogeneous disease an individual approach is required, leading to reduction of symptoms with the least invasive therapy, carefully balancing risk and benefits.

(PDF emailed within 1 workday: $29.90)

Accession: 035980976

Download citation: RISBibTeXText


Related references

Combined h 1 and h 2 antihistamine treatment for chronic urticaria. Journal of Allergy & Clinical Immunology 65(3): 189-190, 1980

Antihistamine treatment: self-assessment in chronic urticaria. British Medical Journal 284(6310): 193-193, 1982

Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. Journal of the European Academy of Dermatology and Venereology 22(4): 481-486, 2007

Dimethpyrindene and a new antihistamine HS 592 in the treatment of severe chronic urticaria. Acta Allergol 23(1): 24-34, 1968

Treatment of chronic urticaria with a new synthetic antihistamine: astemizole. Giornale Italiano di Dermatologia E Venereologia 119(5): Xvii-Xvxx, 1984

Antihistamine treatment: a patient self-assessment method in chronic urticaria. British Medical Journal 283(6304): 1435-1436, 1981

Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults. Annals of Allergy, Asthma and Immunology 117(2): 204-206, 2017

Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. British Journal of Dermatology 119(1): 67-71, 1988

An Assessment of the Novel Antihistamine BW 825C in the Treatment of Chronic Idiopathic Urticaria. Dermatology 169(4): 179-183, 1984

Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine. Giornale Italiano di Dermatologia E Venereologia 2019, 2019

Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria. Dermatologic Therapy 25(4): 379-381, 2013

Dimethpyrindene and a new antihistamine HS 592 (sandoz) in the treatment of severe chronic urticaria. Acta Allergologica 23(1): 24-34, 1968

Features of Antihistamine-Resistant Chronic Urticaria and Chronic Urticaria During Exacerbation. Indian Journal of Dermatology 60(3): 323, 2015

Treatment of chronic idiopathic urticaria unresponsive to type 1 antihistamines in monotherapy. Annales de Dermatologie et de Venereologie 130 Spec No 1: 1s129-1s144, 2003

Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab. Turk Pediatri Arsivi 53(4): 250-254, 2019